Loading the latest PSX data…
Loading the latest PSX data…
Highnoon Laboratories LimitedShariah-compliantKSE-100
+8.50 (+0.89%) today
Market closed, last update Nov 17, 2026 11:52 PMThe Highnoon Laboratories share price was Rs 965.26 (+0.89%) at the last PSX update (Nov 17, 2026 11:52 PM). HINOON is a pharmaceuticals stock in the KSE-100 index with a market value of Rs 51.1bn.
Last session's range17 Nov 2026
957.1069% up the range968.98
52-week range
755.5655% up the range1,140.00
Price limits (circuit breakers)
861.0854% up the range1,052.44
HINOON ranks better than 78% of the 311 liquid PSX stocks we score. Each factor is a 0-100 rank (value is ranked half within pharmaceuticals). Education only, not a buy or sell signal.
+0.7% over 6M(KSE-100 +5.5%)
Daily bars from PSX's end-of-day market summary. Prices before a bonus issue, right issue or split are adjusted so the chart stays continuous; cash dividends are not taken out.
Full-screen HINOON chart with levelsDownload HINOON price history (CSV)Compare HINOON with GLAXO
From daily closes to 2026-11-17. A description of the trend, not a forecast.
Trend reading
Uptrend
Down4 up · 1 down signalsUp
| S2 | S1 | Pivot | R1 | R2 |
|---|---|---|---|---|
| 951.90 | 958.58 | 963.78 | 970.46 | 975.66 |
+120.4% over 5 years
Monthly closing prices from the PSX Data Portal, since 2000. Earlier prices are adjusted for 19 bonus issues and splits (2000–2023; one share then is about 11.1 shares now) so the line shows the value of one original share.
| Announced | Period | Payout | Profit after tax | EPS (Rs) | Books close |
|---|---|---|---|---|---|
| 27 Oct 15:52 | 9 months to 30 Sept | None | – | 51.22 | – |
| 27 Oct 15:51 | 9 months to 30 Sept | None | Rs 2,621.1m | 49.47 | – |
| 27 Aug 15:32 | Half year to 30 Jun | None | – | 33.66 | – |
| 27 Aug 15:31 | Half year to 30 Jun | None | Rs 1,677.5m | 31.66 | – |
| 29 Apr 15:41 | 1st quarter to 31 Mar | None | – | 19.78 | – |
| 29 Apr 15:41 | 1st quarter to 31 Mar | None | Rs 955.7m | 18.04 | – |
| 7 Apr 16:01 | Full year to 31 Dec | None | – | 77.92 | – |
| 7 Apr 16:00 | Full year to 31 Dec | Final cash dividend 500% | Rs 4,119.3m | 77.75 | 23 Apr – 30 Apr |
Measured from October 2021 to October 2026 using PSX daily closes.
For comparison, the KSE-100 (which includes reinvested dividends) returned about 30.5% a year over the same five years, an unusually strong period. Past returns do not predict future ones.
| Measure | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Sales growth | +11.2% | +19.4% | +22.8% | – |
| Profit growth | +26.6% | +35.4% | −0.6% | – |
| EPS growth | +26.6% | +35.4% | −0.6% | – |
| Net margin | 16.0% | 14.0% | 12.4% | 15.3% |
| Measure | Q3 2026 | Q2 2026 | Q1 2026 | Q3 2025 |
|---|---|---|---|---|
| Sales growth | +0.6% | – | – | – |
| Profit growth | −5.7% | – | – | – |
| EPS growth | −5.7% | – | – | – |
| Net margin | 14.3% | 12.2% | 14.0% | 15.2% |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Sales | Rs 25.8bn | Rs 23.2bn | Rs 19.4bn | Rs 15.8bn |
| Profit after tax | Rs 4.1bn | Rs 3.3bn | Rs 2.4bn | Rs 2.4bn |
| Earnings per share (Rs) | 77.75 | 61.41 | 45.35 | 45.62 |
| Line item | Q3 2026 | Q2 2026 | Q1 2026 | Q3 2025 |
|---|---|---|---|---|
| Sales | Rs 6.6bn | Rs 5.9bn | Rs 6.8bn | Rs 6.6bn |
| Profit after tax | Rs 944m | Rs 722m | Rs 956m | Rs 1.0bn |
| Earnings per share (Rs) | 17.81 | 13.62 | 18.04 | 18.89 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Gross margin | 54.8% | 51.4% | 47.6% | 50.8% |
| Net margin | 16.0% | 14.0% | 12.4% | 15.3% |
| EPS growth | 26.6% | 35.4% | -0.6% | 5.7% |
| PEG | 0.49 | 0.42 | -18.80 | 2.09 |
Rupee amounts from PSX filings (thousands converted to Rs m/bn). Data by Capital Stake via the PSX Data Portal; standardised, so it can differ from the annual report. Latest quarter (Q3 2026) EPS fell 5.7% from the same quarter a year earlier.
| Measure | HINOON | Sector median | Reading |
|---|---|---|---|
| P/E | 12.4 | 12.1 | Dearer than peers |
| Dividend yield | 5.4% | 4.7% | Above peers |
| Net margin | 16.0% | 8.8% | Above peers |
| EPS growth | +26.6% | +34.5% | Below peers |
| 1-year return | −14.3% | −13.1% | Below peers |
Sector P/E check. At the sector's median P/E of 12.1, last year's EPS of Rs 77.75 would price HINOON at about Rs 941.53 (−2% from today). A rough yardstick only: sectors hold very different businesses, and the market prices future profits, not last year's.
Estimate a fair value for HINOON (Graham, Lynch, DCF)HINOON pivot levels
Ratios as published on the PSX Data Portal (standardised by Capital Stake), latest financial year on the right.
Work out your HINOON dividend income after tax
| Announced | Period to | Payout | Cash per share | Books closed |
|---|---|---|---|---|
| 7 Apr 2026 | 31 Dec 2025 | Final cash dividend 500% | Rs 50.00 | 23 Apr 2026 – 30 Apr 2026 |
PSX quotes payouts as a percentage of face value; cash per share assumes the usual Rs 10 face value. You get the dividend if you own the shares before the books close.
Market value
4th of 18
Rs 51.1bn
P/E (cheapest first)
8th of 13
12.4
Dividend yield
3rd of 7
5.4%
1-year return
8th of 15
-14.3%
EPS growth
9th of 15
26.6%
Net margin
1st of 16
16.0%
danioPSX score
3rd of 13
78/100
| GLAXOGlaxoSmithKline Pakistan Limited | Rs 106.1bn | −1.89% | 9.7 | 6.1% | −15.4% | 87 |
| ABOTAbbott Laboratories (Pakistan) Limited | Rs 98.5bn | +0.18% | 10.6 | 4.4% | −7.6% | 81 |
| HALEONHaleon Pakistan Limited | Rs 79.8bn | −1.15% | 12.2 | 3.6% | −16.6% | 67 |
| HINOONThis stock · Highnoon Laboratories Limited | Rs 51.1bn | +0.89% | 12.4 | 5.4% | −14.3% | 78 |
| SEARLThe Searle Company Limited | Rs 46.6bn | −0.37% | 12.0 | – | −23.6% | 53 |
| AGPAGP Limited | Rs 43.2bn | −0.84% | 24.1 | 5.1% | −18.3% | 49 |
| HPLHoechst Pakistan Limited | Rs 38.8bn | +0.53% | 11.1 | 6.9% | −2.7% | – |
| FEROZFerozsons Laboratories Limited | Rs 15.7bn | −0.96% | 22.8 | 1.6% | −9.0% | 39 |
| CPHLCiti Pharma Ltd. | Rs 14.4bn | −0.74% | 17.7 | – | −23.2% | 31 |
| GSKCHGlaxoSmithKline Consumer Healthcare | Rs 14.1bn | −3.13% | – | – | – | – |
| BFBIOBF Biosciences Limited | Rs 12.0bn | −0.60% | 18.2 | – | −10.8% | 45 |
| MACTERMacter International Limited | Rs 11.7bn | −1.08% | 3.7 | – | −27.9% | 52 |
| SAPLSanofi-Aventis Pakistan Limited | Rs 8.4bn | 0.00% | – | – | – | – |
| OTSUOtsuka Pakistan Limited | Rs 5.7bn | +0.79% | 11.6 | – | +39.6% | 65 |
| LIVENLiven Pharma Limited | Rs 5.4bn | +10.00% | – | – | −2.3% | 15 |
Swipe the table sideways for more columns.
| Date | Who | Trade | Shares | Price | Value | Holding after | Notice |
|---|---|---|---|---|---|---|---|
| 15 Oct 26 | Mrs. Tehmina Saeed ChaudhuaryNon-Executive Director | SoldReady | 10,000 | 816.71 | Rs 8.2m | 10,000 | Notice |
Read automatically (OCR) from the disclosure images companies file with PSX under Regulation 5.6.1(d). A digit can be misread, so check the original notice before relying on a figure. Value = shares × price. Not investment advice. All PSX insider trades
Highnoon Laboratories Limited (“the Company”) was incorporated in Pakistan under the repealed Companies Ordinance 1984 (now Companies Act, 2017) (“the Act”) and its shares are quoted on Pakistan Stock Exchange since November 1994. The Company is principally engaged in the manufacture, import, sale and marketing of pharmaceutical and related consumer products.
Where the price sits in its 52-week range
Low 755.5655% of the way upHigh 1,140.00
Data: PSX Data Portal (Nov 17, 2026 11:52 PM); company data refreshed 17 Nov; daily bars from PSX market summaries; five-year record from danioPSX research. Logos are trademarks of their owners. Not a recommendation to buy or sell HINOON. Official PSX page for HINOON